Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,150,640
  • Shares Outstanding, K 567,852
  • Annual Sales, $ 25,424 M
  • Annual Income, $ 7,264 M
  • 60-Month Beta 0.68
  • Price/Sales 4.90
  • Price/Cash Flow 9.84
  • Price/Book 15.59
Trade AMGN with:

Options Overview Details

View History
  • Implied Volatility 23.82%
  • Historical Volatility 17.25%
  • IV Percentile 44%
  • IV Rank 26.30%
  • IV High 42.23% on 10/28/20
  • IV Low 17.25% on 06/17/21
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4,713
  • Volume Avg (30-Day) 8,261
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 73,535
  • Open Int (30-Day) 98,057

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 4.13
  • Number of Estimates 10
  • High Estimate 4.45
  • Low Estimate 3.31
  • Prior Year 4.37
  • Growth Rate Est. (year over year) -5.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
213.55 +0.89%
on 09/10/21
227.44 -5.27%
on 08/23/21
-8.08 (-3.61%)
since 08/20/21
3-Month
213.55 +0.89%
on 09/10/21
250.39 -13.95%
on 07/20/21
-24.79 (-10.32%)
since 06/21/21
52-Week
210.28 +2.46%
on 10/29/20
276.69 -22.13%
on 01/28/21
-27.74 (-11.41%)
since 09/21/20

Most Recent Stories

More News
Biosimilar Market Report 2021: Increased Investments, Product Launches, and Collaborations to Spur Growth – Forecast to 2026

The is expected to exceed more than US$ 23.50 Billion by 2024 at a CAGR of 31% in the given forecast period.

PFE : 43.98 (-0.50%)
TEVA : 8.66 (-0.35%)
AMGN : 215.59 (+0.22%)
Global Multiple Myeloma Treatment Drugs Market Global Industry Trends, Competition Strategies and Revenue Analysis 2029

Research Nester released a report titled which delivers detailed overview of the global multiple myeloma treatment drugs market in terms of market segmentation by drug class, therapy, distribution channel,...

BMY : 60.42 (-0.13%)
AMGN : 215.59 (+0.22%)
JNJ : 164.81 (+0.61%)
MRK : 72.14 (+0.29%)
PFE : 43.98 (-0.50%)
SAN : 3.40 (unch)
NOVN : 8.44 (+2.30%)
PHM : 47.13 (-0.51%)
Global Sterile Injectable Drugs Market Growth to be Propelled by Increasing R&D Initiatives to Witness Considerable GAGR throughout 2021-2029

Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution...

SAN : 3.40 (unch)
PFE : 43.98 (-0.50%)
GSK : 39.11 (+0.67%)
BHC : 28.25 (+8.20%)
ABBV : 107.18 (+0.73%)
AMGN : 215.59 (+0.22%)
NOVN : 8.44 (+2.30%)
PROG : 0.9369 (-0.33%)
JNJ : 164.81 (+0.61%)
Amgen Wins Patent Case on Otezla® (apremilast)

/PRNewswire/ -- Amgen today announced that the U.S. District Court for the District of has upheld patents that protect Amgen's psoriasis therapy Otezla (apremilast) in a patent infringement lawsuit against...

AMGN : 215.59 (+0.22%)
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

MRK : 72.14 (+0.29%)
LLY : 230.21 (-0.62%)
AMGN : 215.59 (+0.22%)
MRTX : 166.65 (-6.09%)
Global Multiple Myeloma Treatment Drugs Market Industry Analysis, Size, Growth, Trends, and Forecast 2029

Research Nester released a report titled which delivers detailed overview of the global multiple myeloma treatment drugs market in terms of market segmentation by drug class, therapy, distribution channel,...

BMY : 60.42 (-0.13%)
AMGN : 215.59 (+0.22%)
JNJ : 164.81 (+0.61%)
MRK : 72.14 (+0.29%)
PFE : 43.98 (-0.50%)
SAN : 3.40 (unch)
NOVN : 8.44 (+2.30%)
PHM : 47.13 (-0.51%)
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030

Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region....

SIOX : 2.17 (+2.84%)
PFE : 43.98 (-0.50%)
BAYN : 0.0100 (unch)
BHC : 28.25 (+8.20%)
ABBV : 107.18 (+0.73%)
AMGN : 215.59 (+0.22%)
NOVN : 8.44 (+2.30%)
PROG : 0.9369 (-0.33%)
Oncolytic Virotherapy Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2029

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the oncolytic virotherapy marketn terms of market segmentation by cancer...

AMGN : 215.59 (+0.22%)
SRNE : 7.99 (+0.25%)
Global Sterile Injectable Drugs Market to Witness Considerable growth throughout 2021-2029

Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution...

SAN : 3.40 (unch)
PFE : 43.98 (-0.50%)
GSK : 39.11 (+0.67%)
BHC : 28.25 (+8.20%)
ABBV : 107.18 (+0.73%)
AMGN : 215.59 (+0.22%)
NOVN : 8.44 (+2.30%)
PROG : 0.9369 (-0.33%)
JNJ : 164.81 (+0.61%)
DiGeorge Syndrome Drug Market Propelled by Increased Patient Pool and R&D Initiatives to Witness Substantial GAGR throughout 2021-2029

Research Nester released a report titled "" which delivers detailed overview of the DiGeorge syndrome drug market in terms of market segmentation by therapy type, route of administration, end-user, and...

PFE : 43.98 (-0.50%)
CERC : 2.93 (-1.68%)
BHC : 28.25 (+8.20%)
NTRA : 124.12 (+3.71%)
ABBV : 107.18 (+0.73%)
AMGN : 215.59 (+0.22%)
NOVN : 8.44 (+2.30%)
PROG : 0.9369 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

3rd Resistance Point 224.12
2nd Resistance Point 221.99
1st Resistance Point 218.55
Last Price 215.59
1st Support Level 212.97
2nd Support Level 210.84
3rd Support Level 207.40

See More

52-Week High 276.69
Fibonacci 61.8% 251.32
Fibonacci 50% 243.49
Fibonacci 38.2% 235.65
Last Price 215.59
52-Week Low 210.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar